haematologynow.com Report : Visit Site

Technical data of the haematologynow.com

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host haematologynow.com. Currently, hosted in United States and its service provider is Merit Network Inc. .

the related websites

samsung.com greatrun.org whc.unesco.org fairmont.com lboro.ac.uk theregister.co.uk glenigan.com nhm.ac.uk nationalgallery.org.uk 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Apache/2.4.18 (Ubuntu) containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

-- -- forum is intended for use by healthcare professionals and not patients. you should always contact your doctor or medical professional for further help and advice. skip to content haematological cancers home summary about advisory panel contact us views & reviews viewpoints: highlights from ash news meeting reports viewpoints: highlights from post-ash 2011 viewpoints: highlights from post-ash 2012 resources trial glossary links slides register   -- -- « 01 slides 02 trial glossary 03 links » pause frontpage slideshow (version 2.0.0) - copyright © 2006-2008 by joomlaworks -- have we hit the glass ceiling in the treatment of aml? professor charles craddock, centre for clinical haematology university hospitals birmingham nhs foundation trust queen elizabeth hospital, queen elizabeth medical centre birmingham, uk presentation at the 8 th national annual post-ash update seminar, 11 march 2011 birmingham, uk while outcomes have steadily improved in younger and, to a more modest extent, older adults with acute myeloid leukaemia (aml), disease relapse remains the major cause of treatment failure. in addition, in many older adults conventional chemotherapy is associated with unacceptable toxicity. allogeneic transplantation plays a central role in the management of adult aml. improving results with alternative donors and the advent of reduced intensity regimens now make allografting the cornerstone of management in high risk aml. combining reduced intensity conditioning (ric) allografts with adjunctive targeted therapies may provide a strategy for dissociating graft versus host disease (gvhd) and graft versus leukaemia (gvl). epigenetic therapies show activity in aml with modest toxicity and require further evaluation. leukaemic stem/progenitor cells may be an important biomarker in aml. click here to download slides myelodysplastic syndrome – current issues in improving outcomes dr samir agrawal, consultant haemato-oncologist, st bartholomews and the london nhs trust, london, uk presentation at the 8 th national annual post-ash update seminar, 11 march 2011 birmingham, uk myelodysplastic syndrome (mds) is a heterogeneous group of closely related clonal haematopoietic disorders that primarily affects the elderly. the disease course differs; some patients have indolent disease whereas in others disease is aggressive with a very short clinical course that converts into an acute form of leukaemia. in this presentation dr agrawal describes some of the more recent developments in clinical management of mds, with a focus on messages from ash 2010 and ongoing trials of the mds subgroup of the ncri haematology- oncology clinical studies group. click here to download slides problems in diagnosis and improving outcomes in amyloidosis dr ashutosh wechalekar senior lecturer and honorary consultant, national amyloidosis centre, ucl medical school (royal free campus), london, uk presentation at the 8 th national annual post-ash update seminar, 11 march 2011 birmingham, uk amyloidosis is a rare protein folding disorder caused by an underlying plasma cell dyscrasia and is rapidly fatal in the absence of treatment. chemotherapy for amyloidosis has been adapted from myeloma - often with a higher incidence of toxicity. prospective trials in amyloidosis have been limited. in this presentation dr wechalekar discusses the problems in diagnosis of amyloidosis and recent developments for improving outcome. click here to download slides improving outcomes in myeloma – how many and in which order should we use novel agents? professor antonio palumbo, myeloma unit, division of hematology, university of torino, italy presentation at the 8 th national annual post-ash update seminar, 11 march 2011 birmingham, uk the outcome of patients with myeloma has been substantially improved with the availability of novel agents, resulting in extended relapse-free intervals. in this presentation, professor palumbo discusses treatment strategies, new treatment options and proposals for the standard of care in elderly myeloma patients. click here to download slides improving outcomes in cll professor peter hillmen, consultant haematologist, st james university hospital, leeds, uk presentation at the 8 th national annual post-ash update seminar, 11 march 2011 birmingham, uk the treatment of chronic lymphocytic leukaemia (cll) is rapidly evolving. key areas of interest include tailoring therapy by biological markers, earlier use of allogeneic stem-cell transplantation and strategies aimed at improving management in the elderly and/or unfit patient. here professor hillmen reviews recent and ongoing trials which are evaluating novel approaches to improving outcome. he also discusses a recent trial evaluating eculizumab treatment in paroxysmal nocturnal haemoglobinuria (pnh). click here to download slides more articles... ash 2010 highlights highlights of ash 2011 update of research in west midlands – regional perspective managing highly aggressive dlbcl page 1 of 32 « start prev 1 2 3 4 5 6 7 8 9 10 next end » unless otherwise indicated, opinions expressed in are those of the contributors. although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the sponsor, publisher, editors or the editorial board is accepted for the consequences of any misleading or inaccurate information. © 2014 . all rights reserved. 'viewpoints' photo courtesy of the american society of hematology. username password remember me forgot your password? forgot your username? create an account

URL analysis for haematologynow.com

https://www.haematologynow.com/index3f48.html?start=35
https://www.haematologynow.com/component/user/remind.html
https://www.haematologynow.com/views-a-reviews/meeting-reports.html
https://www.haematologynow.com/about-haematology-now/contact-us.html
https://www.haematologynow.com/managing-highly-aggressive-dlbcl.html
https://www.haematologynow.com/images/stories/slides/cll%20hillmen%20approved%20post%20ashb.ppt
https://www.haematologynow.com/ash-2010-highlights.html
https://www.haematologynow.com/index9075.html?start=15
https://www.haematologynow.com/images/stories/slides/improving%20outcomes%20-%20palumbo.ppt
https://www.haematologynow.com/resources/links.html
https://www.haematologynow.com/index71f1.html?start=25
https://www.haematologynow.com/views-a-reviews/viewpoints-highlights-from-post-ash-2011.html
https://www.haematologynow.com/index795a.html?start=30
https://www.haematologynow.com/about-haematology-now/advisory-panel.html
https://www.haematologynow.com/views-a-reviews/viewpoints.html

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: HAEMATOLOGYNOW.COM
Registry Domain ID: 1635800507_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.123-reg.co.uk
Registrar URL: http://www.meshdigital.com
Updated Date: 2018-02-28T21:00:15Z
Creation Date: 2011-01-19T09:40:48Z
Registry Expiry Date: 2019-01-19T09:40:48Z
Registrar: 123-Reg Limited
Registrar IANA ID: 1515
Registrar Abuse Contact Email:
Registrar Abuse Contact Phone:
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Name Server: NS.123-REG.CO.UK
Name Server: NS2.123-REG.CO.UK
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2018-03-17T13:37:04Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR 123-Reg Limited

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =haematologynow.com

  PORT 43

  TYPE domain

DOMAIN

  NAME haematologynow.com

  CHANGED 2018-02-28

  CREATED 2011-01-19

STATUS
clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
clientTransferProhibited https://icann.org/epp#clientTransferProhibited
clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited

NSERVER

  NS.123-REG.CO.UK 212.67.202.2

  NS2.123-REG.CO.UK 62.138.132.21

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .